Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 12.1% year on year to $2.96 billion. The company expects the full ...

Vertex Pharmaceuticals ( NASDAQ: VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet ...

Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the company announced its experimental pain drug, VX-993, failed a key mid-stage clinical trial ...

Vertex Pharmaceuticals Inc (VRTX) reports a 12% revenue increase and successful product launches, while addressing challenges ...

Vertex Pharmaceuticals (VRTX) posts strong Q2 earnings and revenue growth but faces a 17% stock drop after mid-stage pain drug failure. Read more here.

CRISPR Therapeutics (CRSP) stock falls as company's Q2 results miss consensus amid focus on its Cagevy gene therapy developed with Vertex Pharma (VRTX). Read more here.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting earnings this Monday after the bell. Here’s what to ...

Over the last five years, Vertex's stock has displayed a trend of positive one-day returns in 58% of cases following earnings ...

Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals. Looking at options history for Vertex Pharmaceuticals (NASDAQ: VRTX) we detected 11 trades.

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Vertex Pharmaceuticals ...

Finally, add Applied Digital (NASDAQ: APLD) to your list of brilliant growth stocks to buy and hold for the long haul. It's an opportunity hiding in plain sight.

U.S. stock futures are pointing higher after indexes surged Monday to rebound from last week's selloff. Nasdaq futures are 0.4% higher after the tech-heavy index gained 2% in the prior session, while ...